Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer

Purpose: The ASCENT trial demonstrated the efficacy of sacituzumab govitecan for the treatment of advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of receiving sacituzumab govitecan compared with standard of care chemotherapy from the Un...

Full description

Bibliographic Details

Published in:	Breast
Main Authors:	Yitian Lang, Qingqing Chai, Wenqi Tao, Yahui Liao, Xiaoyan Liu, Bin Wu
Format:	Article
Language:	English
Published:	Elsevier 2023-04-01
Subjects:	Cost-effectiveness Triple-negative breast cancer Sacituzumab govitecan Cure model Partitioned survival approach
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977623000267